Diversified Trust Co Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Diversified Trust Co boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,020 shares of the company’s stock after buying an additional 461 shares during the quarter. Diversified Trust Co’s holdings in Cencora were worth $11,014,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Concord Wealth Partners acquired a new stake in shares of Cencora in the 3rd quarter worth approximately $30,000. SYSTM Wealth Solutions LLC acquired a new stake in Cencora in the second quarter valued at $36,000. Ashton Thomas Securities LLC purchased a new position in shares of Cencora in the third quarter valued at $41,000. Fairscale Capital LLC acquired a new position in shares of Cencora during the 2nd quarter worth $54,000. Finally, Modus Advisors LLC purchased a new stake in shares of Cencora in the 4th quarter worth about $54,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 1.6 %

Shares of COR stock traded up $3.64 during trading hours on Tuesday, hitting $232.52. 267,399 shares of the company were exchanged, compared to its average volume of 921,435. The firm has a fifty day moving average of $237.34 and a 200 day moving average of $233.53. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 1 year low of $208.58 and a 1 year high of $253.27. The firm has a market cap of $44.94 billion, a PE ratio of 30.96, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.95%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is presently 29.29%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on COR shares. Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.